HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

Providing feedback following point-of-care urine testing for tenofovir concentrations was associated with increased PrEP ...

Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir.

Millions of people are going to die,' says The Small Project co-founder of cuts that will likely stop free access to HIV ...

In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...

The results, published in Current Oncology in December, showed 88 per cent of participants chose the self-sample option and ...

Older adults with HIV are at significantly higher risk for cutaneous malignancies when compared with younger patients with HIV.

Incident HCV infection more than doubled among HIV-positive MSM with no history of injection drug use between 1995 and 2023.

Disparities in HIV diagnosis rates were observed between Black and White individuals in the US from 2017 to 2021.

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...